Evolving mechanisms of action of beta blockers: Focus on nebivolol

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 2, 2009, Pages 123-128

  Mason, R Preston ^a,b   Giles, Thomas D ^c   Sowers, James R ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

blockers; Adrenergic beta antagonist; Antihypertensive; Nebivolol; Nitric oxide; Vasodilator agent

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR; BETAXOLOL; BEVANTOLOL; BISOPROLOL; BOPINDOLOL; BUCINDOLOL; CARTEOLOL; CARVEDILOL; CELIPROLOL; ESMOLOL; LABETALOL; METOPROLOL; NADOLOL; NEBIVOLOL; NIPRADILOL; NITRIC OXIDE; PENBUTOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TILISOLOL; TIMOLOL;

CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZOPYRANS; ETHANOLAMINES; HUMANS; HYPERTENSION; NITRIC OXIDE; RECEPTORS, ADRENERGIC, BETA; VASODILATION;

EID: 74249098796     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181ad207b     Document Type: Review

References (37)

1. Frishman WH. b-adrenergic blockers. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner & Rector's The Kidney. 2nd ed. Philadelphia: Elsevier Saunders; 2005:653-659.
2. Nagatomo T, Ohnuki T, Ishiguro M, et al. β-adrenoceptors: threedimensional structures and binding sites for ligands. Jpn J Pharmacol. 2001;87:7-13.
3. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2005:271-291.
4. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. 2004;25: 1341-1362.
5. Arner P. The β3-adrenergic receptor-a cause and cure of obesity? New Engl J Med. 1995;333:382-383.
6. 2 adrenergic receptor. Proc Natl Acad Sci USA. 2001;98:5997-6002.
7. 2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem. 2005;280:22165-22171.
8. 2 adrenoceptor. Insights from fluorescence resonance energy transfer studies. J Biol Chem. 2007;282: 13895-13905.
9. Vilardaga J-P, Steinmeyer R, Harms GS, et al. Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol. 2005;1:25-28.
10. Azzi M, Charest PG, Angers S, et al. B-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein coupled-receptors. Proc Natl Acad Sci USA. 2003;100: 11406-11411.
11. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of b-blocker action: carvedilol stimulates b-arrestin signaling. Proc Natl Acad Sci USA. 2007;104:16657-16662.
12. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006;70:1575-1584.
13. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L-40L.
14. 2- adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43: 203-243.
15. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26: 215-225.
16. Izzo JL Jr. The sympathetic nervous system in acute and chronic blood pressure elevation. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner & Rector's The Kidney. 2nd ed. Philadelphia: Elsevier Saunders; 2005;653-659.
17. Frishman WH. α- and β-adrenergic blocking drugs. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics Manual. New York: McGraw-Hill Medical Publishing Division, 2004: 19-57
18. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980;100:160-178.
19. Bristow MR, Nelson P, MinobeW, et al. Characterization of b1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens. 2005;18:51A-52A.
20. Mason RP, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens. 2006;8(Suppl 4):40-52.
21. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
22. Packer M. β-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41(Suppl 1): 39-52.
23. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA. 1993;90:6189-6193.
24. Naccarelli GV, Lukas MA. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol. 2005;28:165-173.
25. Cockcroft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005;18(12 Pt 2):177S-183S.
26. Mason RP, Kubant R, Jacob RF, et al. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol. 2006;48:862-869.
27. Mangrella M, Rossi F, Fici F, et al. Pharmacology of nebivolol. Pharmacol Res. 1998;38:419-432.
28. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a thirdgeneration beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684.
29. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Thirdgeneration β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747-2752.
30. 3- adrenoceptor agonist and a1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol. 2006;147:699-706.
31. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795-3801.
32. Panza JA, Quyyumi AA, Brush JE Jr, et al. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
33. Campia U, Choucair WK, Bryant MB, et al. Reduced endotheliumdependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol. 2002;40:754-760.
34. Cardillo C, Kilcoyne CM, Cannon RO, et al. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998;31:1235-1239. (Pubitemid 28248821)
35. Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460-463.
36. Tzemos N, Lim PO, MacDonald T. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511-514.
37. Kamp O, Sieswarda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92: 344-348.